OMH Osmetech

RNS Number:3730B
Osmetech PLC
02 April 2001


           OSMETECH SUBMITS E-NOSE TECHNOLOGY
                    FOR FDA APPROVAL


* Submission made to U.S. Food and Drug Administration
  for regulatory approval of UTI sensor technology

* First for any e-nose company

* Remain on track to receive FDA approval by autumn 2001


Osmetech  plc ("Osmetech" or "the Company"), the  world's
leading electronic nose ("e-nose") company for healthcare
applications  today  announces  that  it   has   made   a
submission to US Food and Drug Administration ("FDA") for
approval  of  its  Urinary Tract Infection  (UTI)  sensor
technology.

In   January,   the  Company  announced   that   it   had
successfully  completed  FDA  clinical  trials  for   the
detection of urinary tract infections.  These performance
results, better than expected, have now been submitted to
the FDA. This FDA submission is a landmark achievement in
the e-nose industry.

FDA  approval for the Company's first diagnostic test  is
expected   by   autumn  2001,  a  major  endorsement   of
Osmetech's core technology.



Enquiries:

Osmetech plc                       01270 216 444
James White, Chief Executive

Bell Pottinger Financial           020 7353 9203
Matthew Moth/Rebecca Fox



Notes to Editors

* Osmetech plc designs, develops and manufactures
  electronic gas and odour sensors (electronic noses) for
  use in the healthcare sector. Osmetech's multi-sensor
  array based gas sensing technology screens patient
  samples and tests for the presence of infection-causing
  bacteria.

* The Company, which is based in Crewe, is currently
  focusing its IP development on sensors that can detect
  bacteria associated with urinary tract infections
  (UTIs), bacterial vaginosis (BV) and pneumonia in ICU
  patients.

* FDA approval of Osmetech's UTI sensor technology would
  represent the strongest possible regulatory endorsement
  of  the  Company's  core technology.  It  would  enable
  Osmetech to market its product to licensing partners in
  the  United  States, where the size of  the  healthcare
  market provides enormous opportunities.

* Every year there are 50 million Urinary Tract
  Infections (UTI) tests in the US. The average cost per
  test is at least $5.

* In January 2000, Osmetech announced that its first set
  of trials for its UTI product had been successful. The
  trials, carried out at St Thomas', London, and the
  Brigham & Women's Hospital, Harvard, USA, enabled the
  company to obtain "proof of concept" status for its
  technology.

* In October 2000, the Board of Osmetech announced that,
  following a large proof of concept study at St George's
  Hospital Medical School, London, Osmetech's Bacterial
  Vaginosis (BV) Microbial Analyser matched the
  diagnostic performance of the existing "gold standard"
  diagnostic test.

Osmetech (LSE:OMH)
Historical Stock Chart
From Jun 2024 to Jul 2024

Osmetech (LSE:OMH)
Historical Stock Chart
From Jul 2023 to Jul 2024